Teprotumumab is a monoclonal antibody that blocks the insulin-like growth factor 1 receptor and treats thyroid eye disease.

It reduces proptosis and diplopia in a way that steroids do not. Therefore, it has changed how clinicians approach moderate to severe active disease.


Mechanism of Teprotumumab

The IGF-1 receptor forms a complex with the thyrotropin receptor in orbital fibroblasts, and blocking it reduces the signal that drives inflammation and tissue expansion. The effect also reduces hyaluronan production and muscle volume, and because the pathway is central, the drug acts on the cause.

The Phase 2 Teprotumumab Trial

Smith and colleagues tested the drug in active disease in 2017, and proptosis response, defined as a reduction of two millimeters or more, occurred in 71 percent of treated patients and 20 percent of controls. The clinical activity score also fell more with treatment, so the trial gave strong early evidence.

Test your knowledge 10 questions from this article
Choroida · Slit-lamp imaging

All-fit Slit-Lamp Adapter

Record and share exactly what you see at the slit lamp. One adapter fits any slit lamp or surgical microscope — and any smartphone.

From Choroida — the team behind this site

The OPTIC Trial

Douglas and colleagues reported OPTIC in 2020, where 83 percent of treated patients met the proptosis endpoint compared with 10 percent of controls. Diplopia also improved in about two thirds of treated patients, and because the effect was large, the drug was approved.

Dosing of Teprotumumab

The regimen is eight infusions given every three weeks, with a first dose of 10 milligrams per kilogram followed by 20 milligrams per kilogram. Each infusion takes 60 to 90 minutes, so patients need planning for visits.

Chronic Disease

Later work tested patients with long duration and low activity, and Douglas and colleagues reported improvement in proptosis in this group. The benefit was smaller than in active disease, and because the data are newer, follow evolving guidance.

Side Effects of Teprotumumab

Muscle spasms, nausea, fatigue and alopecia are common, and hyperglycemia can occur, especially in patients with diabetes. Infusion reactions are also possible, so monitor glucose and counsel patients.

Hearing Impairment With Teprotumumab

Hearing loss, tinnitus and ear fullness occur in a share of patients, and Sears and colleagues described hearing dysfunction after treatment. The effect can persist in some patients, and because it can be permanent, baseline audiometry is advisable.

Contraindications and Cautions

Avoid the drug in pregnancy, and use caution in patients with inflammatory bowel disease. Review diabetes control before treatment, and screen for risk factors.

Relapse After Teprotumumab

A minority of patients relapse after stopping, and retreatment is possible, with similar benefit in some reports. Long-term data are still limited, and because relapse occurs, plan follow-up.

Position in Guidelines

The European guidelines favor intravenous methylprednisolone as first-line therapy, and they consider other agents for steroid-resistant or severe cases. Teprotumumab fills a gap in patients with proptosis and diplopia, so individualize the choice.

Teprotumumab in Thyroid Eye Disease: Evidence and Risks

Orbital Surgery and Radiotherapy

Surgery remains important in inactive disease and for residual deformity, and decompression, strabismus surgery and lid surgery follow a set order. Radiotherapy has limited use, and because treatment is staged, coordinate care.

Monitoring

Measure proptosis, motility and activity at each visit, and check hearing and glucose. Photograph the patient for comparison, because changes are gradual and records help.

Patient Selection

Choose patients with active, moderate to severe disease and proptosis, and also consider those with troublesome diplopia. Because inactive disease responds less, use the clinical activity score and imaging to judge.

Effect on Diplopia and Muscle Volume

In OPTIC, diplopia improved more with treatment than with placebo, and extraocular muscle volume also fell on imaging. Therefore, the drug can reduce the need for strabismus surgery in some patients.

Combining Treatment With Surgery

Orbital decompression may still be needed for residual proptosis or optic neuropathy, and strabismus and lid surgery follow after stabilization. Because timing matters, coordinate with the orbital surgeon.

Optic Neuropathy

Compressive optic neuropathy needs prompt steroids or decompression, and data on the drug in this setting are limited. Do not delay urgent treatment while waiting for the drug.

Cost and Access

The drug is expensive, and coverage varies, while infusion centers are needed for administration. Therefore, start the approval process early.

Practical Counseling Before Infusions

Explain the schedule, the number of infusions and the expected benefit, and tell patients about muscle cramps and hearing symptoms, asking them to report any change early. Advise a baseline hearing test and a glucose check, and because adherence matters, give a written schedule.

Monitoring During and After Therapy

Review proptosis, diplopia and activity at each infusion, and stop the drug and seek advice if hearing symptoms develop. Plan follow-up for several months after the last dose to check for relapse, and therefore treat the course as a monitored program and not as a single prescription.


All-fit smartphone adapter on a slit lampFundus Explorer Pro smartphone fundus camera
Choroida · Clinical imaging

Document what you see

Two smartphone imaging tools built for everyday clinic use — one for the slit lamp, one for the fundus.

From Choroida — the team behind this site

References

  1. Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376:1748-1761.
  2. Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382:341-352.
  3. Sears CM, Azad AD, Amarikwa L, et al. Hearing dysfunction after treatment with teprotumumab for thyroid eye disease. Am J Ophthalmol. 2022;240:1-13.
  4. Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185:G43-G67.

Test yourself

A few questions straight from this article.

1 / 10 0 correct
  1. Which receptor does the monoclonal antibody teprotumumab block in thyroid eye disease?

Ahmed Ophthalmologist

Writes and reviews the clinical articles on Educate. Every post is checked against peer-reviewed sources before it goes live.